# POP-RT

Source: https://nuclide.cc/trials/pop-rt/  
Nuclide record `pop-rt` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

POP-RT, from Mumbai, showed that treating the pelvic lymph nodes as well as the prostate improves disease control in high-risk prostate cancer, reviving a question earlier trials had left unanswered.

## Summary

POP-RT randomised 224 men with high-risk, node-negative prostate cancer (most staged with PSMA PET) to image-guided prostate-only or whole-pelvic radiotherapy with two years of androgen deprivation. Five-year biochemical failure-free survival was 95 percent with pelvic radiotherapy and 81.2 percent with prostate-only treatment (hazard ratio 0.23), with better disease-free survival and more late urinary toxicity (Murthy and colleagues, Journal of Clinical Oncology 2021).

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-27
- Tags: radiation-wave4
- Registry id: NCT02302105
- Phase: 3
- Setting: High-risk node-negative prostate cancer: prostate-only versus whole-pelvic radiotherapy, both with hormone therapy
- Sponsor: Tata Memorial Centre, Mumbai
- Enrolled: 224
- Result: 5-year biochemical failure-free survival 95% (whole pelvis) vs 81.2% (prostate only).
- Outcomes: Biochemical failure-free survival at 5 years: Whole-pelvic radiotherapy 95% vs Prostate-only radiotherapy 81.2%

## Sources

- ClinicalTrials.gov NCT02302105 (POP-RT, Tata Memorial Centre): https://clinicaltrials.gov/study/NCT02302105
- JCO 2021: https://doi.org/10.1200/JCO.20.03282

## Connected records

- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/)

---
JSON: https://nuclide.cc/api/v1/entities/pop-rt.json